Search Results 431-440 of 23343 for B cell lymphomas

  1. Marginal zone lymphoma - Doctors and departments - Mayo Clinic

    Marginal zone lymphoma, B-cell lymphoma, Lymphoma, Hairy cell leukemia, T-cell lymphoma, Small lymphocytic lymphoma, Fo...llicular lymphoma, Hodgkin lymphoma.

  2. Cancer Physicians - Medical Professionals - Mayo Clinic

    Arushi Khurana, M.B.B.S.. Rochester, MN. Area of Focus: Chemotherapy, CAR-T cell therapy, B-cell lymphoma, ...

  3. Clinical trials - Oncology (Medical)

    ... B-cell Lymphoma (R/R DLBCL). Rochester, Minn. Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by ...

  4. Chemotherapy For Clinical Trials - Mayo Clinic Research

    ... B-Cell Lymphoma (DLBCL). A Study to Test the Addition of Nivolumab to Chemotherapy to Treat Soft Tissue Sarcoma Scottsdale/Phoenix, AZ; Jacksonville, FL ...

  5. Clinical trials - Oncology (Medical)

    ... B-cell Lymphoma (R/R DLBCL). Rochester, Minn. Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by ...

  6. Lymphoma - Doctors and departments - Mayo Clinic

    Developing the first genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non-Hodgkin ...

  7. Lymphoma - Doctors and departments - Mayo Clinic

    Developing the first genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non-Hodgkin ...

  8. Clinical trials - Oncology (Medical)

    ... B-cell Lymphoma (R/R DLBCL). Rochester, Minn. Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by ...

  9. Epcoritamab-bysp (subcutaneous route) - Mayo Clinic

    Description. Epcoritamab-bysp injection is used to treat certain types of large B-cell lymphoma (including diffuse large B-cell lymphoma [DLBCL] and high ...

  10. Innovative therapies shape the future of chronic lymphocytic leukemia treatment - Mayo Clinic

    BTK inhibitors work by blocking the B-cell receptor signaling pathway. Then in 2016, the FDA approved the first B-cell lymphoma 2 (BCL-2) inhibitor drug for the ...